NSRX Nasus Pharma, Ltd.: Total Company Value-to-Revenue Ratio

Public company logo of Nasus Pharma Ltd. (NSRX)

Nasus Pharma Ltd (NSRX) develops innovative nasal products, including the antiviral Taffix. The company's price-to-sales ratio reflects asset revaluation dynamics, where the 0.00 metric indicates the status of current value. The team relies on R&D freedom and options for chemical technologists. The environmental profile is based on compliance with medical plastic disposal standards during inhaler production.

Nasus Pharma Ltd - NSRX Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

Nasus Pharma Ltd - analytical breakdowns and key metrics (NSRX)

- current quotes and average value forecast:
- money and cash flow information:
Initial company analysis:Nasus Pharma, Ltd. NSRX
Product sample of Nasus Pharma, Ltd.

This indicator determines the market value of the business accounting for net debt relative to sales volume, allowing for an assessment of the asset's maturity without the influence of debt load. By analyzing the enterprise value-to-revenue ratio, an investor can see to what extent the pricing power of Nasus Pharma Ltd (NSRX) in the emergency nasal drug niche justifies the company's current market capitalization in the eyes of the market.